Publications 2024

Christersson M, Gustafsson S, Lampa E, Almstedt M, Cars T, Bodegård J, Arefalk G, Sundström J (2024)
Usefulness of Heart Failure Categories Based on Left Ventricular Ejection Fraction
J Am Heart Assoc, 13 (8), e032257
DOI 10.1161/JAHA.123.032257, PubMed 38591322

Metsärinne K, Bodegård J, Toppila I, Uusi-Rauva K, Frederiksen LE, Brinkmann S (2024)
Characteristics, treatment and disease burden among stage 3-4 chronic kidney disease patients with and without type 2 diabetes in Finland during 2016-2022
Nephrol Dial Transplant (in press)
DOI 10.1093/ndt/gfae242, PubMed 39510970

Sundström J, Norhammar A, Karayiannides S, Bodegård J, Gustafsson S, Cars T, Eriksson Svensson M, Ärnlöv J (2024)
Are there lost opportunities in chronic kidney disease? A region-wide cohort study
BMJ Open, 14 (4), e074064
DOI 10.1136/bmjopen-2023-074064, PubMed 38643002

Sundström J, Ärnlöv J, Karayiannides S, Bodegard J, Ersmark K, Gustafsson S, Cars T, Svensson MK, Norhammar A (2024)
Heart failure outcomes by left ventricular ejection fraction in a contemporary region-wide patient cohort
ESC Heart Fail, 11 (3), 1377-1388
DOI 10.1002/ehf2.14685, PubMed 38311878

Svensson MK, Tangri N, Bodegård J, Adamsson Eryd S, Thuresson M, Sofue T (2024)
Dapagliflozin treatment of patients with chronic kidney disease without diabetes across different albuminuria levels (OPTIMISE-CKD)
Clin Kidney J, 17 (8), sfae100
DOI 10.1093/ckj/sfae100, PubMed 39165293

Tangri N, Svensson MK, Bodegård J, Adamsson Eryd S, Thuresson M, Gustafsson S, Sofue T (2024)
Mortality, Health Care Burden, and Treatment of CKD: A Multinational, Observational Study (OPTIMISE-CKD)
Kidney360, 5 (3), 352-362
DOI 10.34067/KID.0000000000000374, PubMed 38297439

Publications 2023

Bozkurt B, Savarese G, Adamsson Eryd S, Bodegård J, Cleland JGF, Khordoc C, Kishi T, Thuresson M, Vardeny O, Zhang R, Lund LH (2023)
Mortality, Outcomes, Costs, and Use of Medicines Following a First Heart Failure Hospitalization: EVOLUTION HF
JACC Heart Fail, 11 (10), 1320-1332
DOI 10.1016/j.jchf.2023.04.017, PubMed 37354145

Norhammar A, Bodegard J, Vanderheyden M, Tangri N, Karasik A, Maggioni AP, Sveen KA, Taveira-Gomes T, Botana M, Hunziker L, Thuresson M, Banerjee A, Sundström J, Bollmann A (2023)
Prevalence, outcomes and costs of a contemporary, multinational population with heart failure
Heart, 109 (7), 548-556
DOI 10.1136/heartjnl-2022-321702, PubMed 36781285

Ritsinger V, Bodegård J, Kristofi R, Thuresson M, Nathanson D, Nyström T, Eriksson J, Norhammar A (2023)
History of heart failure and chronic kidney disease and risk of all-cause death after COVID-19 during the first three waves of the pandemic in comparison with influenza outbreaks in Sweden: a registry-based, retrospective, case-control study
BMJ Open, 13 (4), e069037
DOI 10.1136/bmjopen-2022-069037, PubMed 37117003

Publications 2022

Kristófi R, Bodegard J, Ritsinger V, Thuresson M, Nathanson D, Nyström T, Norhammar A, Eriksson JW (2022)
Patients with type 1 and type 2 diabetes hospitalized with COVID-19 in comparison with influenza: mortality and cardiorenal complications assessed by nationwide Swedish registry data
Cardiovasc Diabetol, 21 (1), 282
DOI 10.1186/s12933-022-01719-x, PubMed 36522650

Norhammar A, Bodegard J, Eriksson JW, Haller H, Linssen GCM, Banerjee A, Karasik A, Mamouris P, Tangri N, Taveira-Gomes T, Maggioni AP, Botana M, Thuresson M, Okami S, Yajima T, Kadowaki T, Birkeland KI, CaReMe Cardiorenal Investigators (2022)
Cost of healthcare utilization associated with incident cardiovascular and renal disease in individuals with type 2 diabetes: A multinational, observational study across 12 countries
Diabetes Obes Metab, 24 (7), 1277-1287
DOI 10.1111/dom.14698, PubMed 35322567

Savarese G, Kishi T, Vardeny O, Adamsson Eryd S, Bodegård J, Lund LH, Thuresson M, Bozkurt B (2022)
Heart Failure Drug Treatment-Inertia, Titration, and Discontinuation: A Multinational Observational Study (EVOLUTION HF)
JACC Heart Fail, 11 (1), 1-14
DOI 10.1016/j.jchf.2022.08.009, PubMed 36202739

Schechter M, Melzer Cohen C, Yanuv I, Rozenberg A, Chodick G, Bodegård J, Leiter LA, Verma S, Lambers Heerspink HJ, Karasik A, Mosenzon O (2022)
Epidemiology of the diabetes-cardio-renal spectrum: a cross-sectional report of 1.4 million adults
Cardiovasc Diabetol, 21 (1), 104
DOI 10.1186/s12933-022-01521-9, PubMed 35689214

Sundström J, Bodegard J, Bollmann A, Vervloet MG, Mark PB, Karasik A, Taveira-Gomes T, Botana M, Birkeland KI, Thuresson M, Jäger L, Sood MM, VanPottelbergh G, Tangri N, CaReMe CKD Investigators (2022)
Prevalence, outcomes, and cost of chronic kidney disease in a contemporary population of 2·4 million patients from 11 countries: The CaReMe CKD study
Lancet Reg Health Eur, 20, 100438
DOI 10.1016/j.lanepe.2022.100438, PubMed 36090671

Publications 2021

Falk RS, Mariampillai JE, Prestgaard EE, Heir T, Bodegård J, Robsahm TE, Grundvold I, Skretteberg PT, Engeseth K, Bjornholt JV, Stavem K, Liestøl K, Sandvik L, Thaulow E, Erikssen G, Kjeldsen SE, Gjesdal K, Erikssen JE (2021)
The Oslo Ischaemia Study: cohort profile
BMJ Open, 11 (10), e049111
DOI 10.1136/bmjopen-2021-049111, PubMed 34645662

Khunti K, Kosiborod M, Kim DJ, Kohsaka S, Lam CSP, Goh SY, Chiang CE, Shaw JE, Cavender MA, Tangri N, Franch-Nadal J, Holl RW, Jørgensen ME, Norhammar A, Eriksson JG, Zaccardi F, Karasik A, Magliano DJ, Thuresson M, Chen H, Wittbrodt E, Bodegård J, Surmont F, Fenici P, CVD-REAL Investigators and Study Group (2021)
Cardiovascular outcomes with sodium-glucose cotransporter-2 inhibitors vs other glucose-lowering drugs in 13 countries across three continents: analysis of CVD-REAL data
Cardiovasc Diabetol, 20 (1), 159
DOI 10.1186/s12933-021-01345-z, PubMed 34332558

Komuro I, Kadowaki T, Bodegård J, Thuresson M, Okami S, Yajima T (2021)
Lower heart failure and chronic kidney disease risks associated with sodium-glucose cotransporter-2 inhibitor use in Japanese type 2 diabetes patients without established cardiovascular and renal diseases
Diabetes Obes Metab, 23 Suppl 2, 19-27
DOI 10.1111/dom.14119, PubMed 33835641

Kristófi R, Bodegard J, Norhammar A, Thuresson M, Nathanson D, Nyström T, Birkeland KI, Eriksson JW (2021)
Cardiovascular and Renal Disease Burden in Type 1 Compared With Type 2 Diabetes: A Two-Country Nationwide Observational Study
Diabetes Care, 44 (5), 1211-1218
DOI 10.2337/dc20-2839, PubMed 33653822

Mariampillai JE, Prestgaard EE, Kjeldsen SE, Liestøl K, Grundvold I, Bodegård J, Gjesdal K, Erikssen JE, Skretteberg PT (2021)
Novel insights into stroke risk beyond resting and maximal bicycle exercise systolic blood pressure
J Hypertens, 39 (10), 2022-2029
DOI 10.1097/HJH.0000000000002894, PubMed 34102659

Savarese G, Bodegard J, Norhammar A, Sartipy P, Thuresson M, Cowie MR, Fonarow GC, Vaduganathan M, Coats AJS (2021)
Heart failure drug titration, discontinuation, mortality and heart failure hospitalization risk: a multinational observational study (US, UK and Sweden)
Eur J Heart Fail, 23 (9), 1499-1511
DOI 10.1002/ejhf.2271, PubMed 34132001

Publications 2020

Birkeland KI, Bodegard J, Banerjee A, Kim DJ, Norhammar A, Eriksson JW, Thuresson M, Okami S, Ha KH, Kossack N, Mamza JB, Zhang R, Yajima T, Komuro I, Kadowaki T (2020)
Lower cardiorenal risk with sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes without cardiovascular and renal diseases: A large multinational observational study
Diabetes Obes Metab, 23 (1), 75-85
DOI 10.1111/dom.14189, PubMed 32893440

Birkeland KI, Bodegard J, Eriksson JW, Norhammar A, Haller H, Linssen GCM, Banerjee A, Thuresson M, Okami S, Garal-Pantaler E, Overbeek J, Mamza JB, Zhang R, Yajima T, Komuro I, Kadowaki T (2020)
Heart failure and chronic kidney disease manifestation and mortality risk associations in type 2 diabetes: A large multinational cohort study
Diabetes Obes Metab, 22 (9), 1607-1618
DOI 10.1111/dom.14074, PubMed 32363737

Knudsen ST, Bodegård J, Birkeland KI, Furuseth K, Thuresson M, Lindh A, Nilsson PM, Alvarsson M, Jørgensen ME, Søndergaard J, Persson F (2020)
Risk factor management of type 2 diabetic patients in primary care in the Scandinavian countries between 2003 and 2015
Prim Care Diabetes, 15 (2), 262-268
DOI 10.1016/j.pcd.2020.09.006, PubMed 33032936

Kohsaka S, Lam CSP, Kim DJ, Cavender MA, Norhammar A, Jørgensen ME, Birkeland KI, Holl RW, Franch-Nadal J, Tangri N, Shaw JE, Ilomäki J, Karasik A, Goh SY, Chiang CE, Thuresson M, Chen H, Wittbrodt E, Bodegård J, Surmont F, Fenici P, Kosiborod M, CVD-REAL 2 Investigators and Study Group (2020)
Risk of cardiovascular events and death associated with initiation of SGLT2 inhibitors compared with DPP-4 inhibitors: an analysis from the CVD-REAL 2 multinational cohort study
Lancet Diabetes Endocrinol, 8 (7), 606-615
DOI 10.1016/S2213-8587(20)30130-3, PubMed 32559476

Kohsaka S, Takeda M, Bodegård J, Thuresson M, Kosiborod M, Yajima T, Wittbrodt E, Fenici P (2020)
Sodium-glucose cotransporter 2 inhibitors compared with other glucose-lowering drugs in Japan: Subanalyses of the CVD-REAL 2 Study
J Diabetes Investig, 12 (1), 67-73
DOI 10.1111/jdi.13321, PubMed 32530554

Prestgaard E, Mariampillai J, Engeseth K, Erikssen J, Bodegård J, Liestøl K, Kjeldsen S, Grundvold I, Berge E (2020)
Change in Body Weight and Long-Term Risk of Stroke and Death in Healthy Men
Stroke, 51 (5), 1435-1441
DOI 10.1161/STROKEAHA.119.027233, PubMed 32268850

Publications 2019

Birkeland KI, Bodegard J, Norhammar A, Kuiper JG, Georgiado E, Beekman-Hendriks WL, Thuresson M, Pignot M, Herings RMC, Kooy A (2019)
How representative of a general type 2 diabetes population are patients included in cardiovascular outcome trials with SGLT2 inhibitors? A large European observational study
Diabetes Obes Metab, 21 (4), 968-974
DOI 10.1111/dom.13612, PubMed 30537226

Jernberg T, Lindholm D, Hasvold LP, Svennblad B, Bodegård J, Sundell Andersson K, Thuresson M, Erlinge D, Janzon M (2019)
Impact of ischaemic heart disease severity and age on risk of cardiovascular outcome in diabetes patients in Sweden: a nationwide observational study
BMJ Open, 9 (4), e027199
DOI 10.1136/bmjopen-2018-027199, PubMed 30948612

Mariampillai JE, Liestøl K, Kjeldsen SE, Prestgaard EE, Engeseth K, Bodegard J, Berge E, Gjesdal K, Erikssen J, Grundvold I, Skretteberg PT (2019)
Exercise Systolic Blood Pressure at Moderate Workload Is Linearly Associated With Coronary Disease Risk in Healthy Men
Hypertension, 75 (1), 44-50
DOI 10.1161/HYPERTENSIONAHA.119.13528, PubMed 31735088

Mariampillai JE, Prestgaard EE, Kjeldsen SE, Liestøl K, Engeseth K, Erikssen J, Bodegard J, Berge E, Grundvold I, Skretteberg PT (2019)
SBP above 180 mmHg at moderate exercise workload increases coronary heart disease risk in healthy men during 28-year follow-up
J Hypertens, 37 (5), 949-955
DOI 10.1097/HJH.0000000000001959, PubMed 30325341

Norhammar A, Bodegard J, Nyström T, Thuresson M, Rikner K, Nathanson D, Eriksson JW (2019)
Dapagliflozin vs non-SGLT-2i treatment is associated with lower healthcare costs in type 2 diabetes patients similar to participants in the DECLARE-TIMI 58 trial: A nationwide observational study
Diabetes Obes Metab, 21 (12), 2651-2659
DOI 10.1111/dom.13852, PubMed 31379124

Norhammar A, Bodegård J, Nyström T, Thuresson M, Nathanson D, Eriksson JW (2019)
Dapagliflozin and cardiovascular mortality and disease outcomes in a population with type 2 diabetes similar to that of the DECLARE-TIMI 58 trial: A nationwide observational study
Diabetes Obes Metab, 21 (5), 1136-1145
DOI 10.1111/dom.13627, PubMed 30609272

Publications 2018

Cavender MA, Norhammar A, Birkeland KI, Jørgensen ME, Wilding JP, Khunti K, Fu AZ, Bodegård J, Blak BT, Wittbrodt E, Thuresson M, Fenici P, Hammar N, Kosiborod M, CVD-REAL Investigators and Study Group (2018)
SGLT-2 Inhibitors and Cardiovascular Risk: An Analysis of CVD-REAL
J Am Coll Cardiol, 71 (22), 2497-2506
DOI 10.1016/j.jacc.2018.01.085, PubMed 29852973

Engeseth K, Prestgaard EE, Mariampillai JE, Grundvold I, Liestol K, Kjeldsen SE, Bodegard J, Erikssen JE, Gjesdal K, Skretteberg PT (2018)
Physical fitness is a modifiable predictor of early cardiovascular death: A 35-year follow-up study of 2014 healthy middle-aged men
Eur J Prev Cardiol, 25 (15), 1655-1663
DOI 10.1177/2047487318793459, PubMed 30103630

Farkhooy A, Bodegård J, Erikssen JE, Janson C, Hedenström H, Stavem K, Malinovschi A (2018)
Cross-sectional and longitudinal analyses of the association between lung function and exercise capacity in healthy Norwegian men
BMC Pulm Med, 18 (1), 118
DOI 10.1186/s12890-018-0655-z, PubMed 30021542

Kosiborod M, Birkeland KI, Cavender MA, Fu AZ, Wilding JP, Khunti K, Holl RW, Norhammar A, Jørgensen ME, Wittbrodt ET, Thuresson M, Bodegård J, Hammar N, Fenici P, CVD-REAL Investigators and Study Group (2018)
Rates of myocardial infarction and stroke in patients initiating treatment with SGLT2-inhibitors versus other glucose-lowering agents in real-world clinical practice: Results from the CVD-REAL study
Diabetes Obes Metab, 20 (8), 1983-1987
DOI 10.1111/dom.13299, PubMed 29569378

Kosiborod M, Cavender MA, Fu AZ, Wilding JP, Khunti K, Holl RW, Norhammar A, Birkeland KI, Jørgensen ME, Thuresson M, Arya N, Bodegård J, Hammar N, Fenici P, CVD-REAL Investigators and Study Group (2018)
Response by Kosiborod et al to Letters Regarding Article, "Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors)"
Circulation, 137 (9), 989-991
DOI 10.1161/CIRCULATIONAHA.117.031847, PubMed 29483180

Nathanson D, Sabale U, Eriksson JW, Nyström T, Norhammar A, Olsson U, Bodegård J (2018)
Healthcare Cost Development in a Type 2 Diabetes Patient Population on Glucose-Lowering Drug Treatment: A Nationwide Observational Study 2006-2014
Pharmacoecon Open, 2 (4), 393-402
DOI 10.1007/s41669-017-0063-y, PubMed 29623637

Nyström T, Bodegård J, Nathanson D, Thuresson M, Norhammar A, Eriksson JW (2018)
Comment on Suissa. Lower Risk of Death With SGLT2 Inhibitors in Observational Studies: Real or Bias? Diabetes Care 2018;41:6-10
Diabetes Care, 41 (6), e104-e105
DOI 10.2337/dc18-0339, PubMed 29784707

Persson F, Bodegard J, Lahtela JT, Nyström T, Jørgensen ME, Jensen ML, Gulseth HL, Thuresson M, Hoti F, Nathanson D, Norhammar A, Birkeland KI, Eriksson JG, Eriksson JW (2018)
Different patterns of second-line treatment in type 2 diabetes after metformin monotherapy in Denmark, Finland, Norway and Sweden (D360 Nordic): A multinational observational study
Endocrinol Diabetes Metab, 1 (4), e00036
DOI 10.1002/edm2.36, PubMed 30815564

Prestgaard E, Mariampillai J, Engeseth K, Erikssen J, Bodegård J, Liestøl K, Gjesdal K, Kjeldsen S, Grundvold I, Berge E (2018)
Change in Cardiorespiratory Fitness and Risk of Stroke and Death: Long-Term Follow-Up of Healthy Middle-Aged Men
Stroke, 50 (1), 155-161
DOI 10.1161/STROKEAHA.118.021798, PubMed 30580727

Publications 2017

Birkeland KI, Jørgensen ME, Carstensen B, Persson F, Gulseth HL, Thuresson M, Fenici P, Nathanson D, Nyström T, Eriksson JW, Bodegård J, Norhammar A (2017)
Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL Nordic): a multinational observational analysis
Lancet Diabetes Endocrinol, 5 (9), 709-717
DOI 10.1016/S2213-8587(17)30258-9, PubMed 28781064

Kosiborod M, Cavender MA, Fu AZ, Wilding JP, Khunti K, Holl RW, Norhammar A, Birkeland KI, Jørgensen ME, Thuresson M, Arya N, Bodegård J, Hammar N, Fenici P, CVD-REAL Investigators and Study Group* (2017)
Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors)
Circulation, 136 (3), 249-259
DOI 10.1161/CIRCULATIONAHA.117.029190, PubMed 28522450

Mariampillai JE, Engeseth K, Kjeldsen SE, Grundvold I, Liestøl K, Erikssen G, Erikssen J, Bodegard J, Skretteberg PT (2017)
Exercise systolic blood pressure at moderate workload predicts cardiovascular disease and mortality through 35 years of follow-up in healthy, middle-aged men
Blood Press, 26 (4), 229-236
DOI 10.1080/08037051.2017.1291276, PubMed 28276720

Nyström T, Bodegard J, Nathanson D, Thuresson M, Norhammar A, Eriksson JW (2017)
Novel oral glucose-lowering drugs are associated with lower risk of all-cause mortality, cardiovascular events and severe hypoglycaemia compared with insulin in patients with type 2 diabetes
Diabetes Obes Metab, 19 (6), 831-841
DOI 10.1111/dom.12889, PubMed 28116795

Persson F, Nyström T, Jørgensen ME, Carstensen B, Gulseth HL, Thuresson M, Fenici P, Nathanson D, Eriksson JW, Norhammar A, Bodegard J, Birkeland KI (2017)
Dapagliflozin is associated with lower risk of cardiovascular events and all-cause mortality in people with type 2 diabetes (CVD-REAL Nordic) when compared with dipeptidyl peptidase-4 inhibitor therapy: A multinational observational study
Diabetes Obes Metab, 20 (2), 344-351
DOI 10.1111/dom.13077, PubMed 28771923

Prestgaard E, Hodnesdal C, Engeseth K, Erikssen J, Bodegård J, Liestøl K, Gjesdal K, Kjeldsen SE, Grundvold I, Berge E (2017)
Long-term predictors of stroke in healthy middle-aged men
Int J Stroke, 13 (3), 292-300
DOI 10.1177/1747493017730760, PubMed 28929941

Sabale U, Bodegard J, Svennblad B, Östgren CJ, Johansson G, Ekman M, Henriksson M, Nilsson P (2017)
Weight change patterns and healthcare costs in patients with newly-diagnosed type-2 diabetes in Sweden
Prim Care Diabetes, 11 (3), 217-225
DOI 10.1016/j.pcd.2017.03.001, PubMed 28389199

Publications 2016

Engeseth K, Hodnesdal C, Grundvold I, Liestøl K, Gjesdal K, Kjeldsen SE, Erikssen JE, Bodegard J, Skretteberg PT (2016)
Temporal Reduction in Chronotropic Index Predicts Risk of Cardiovascular Death Among Healthy Middle-Aged Men: a 28-Year Follow-Up Study
J Am Heart Assoc, 5 (12)
DOI 10.1161/JAHA.116.004555, PubMed 27881424

Eriksson JW, Bodegard J, Nathanson D, Thuresson M, Nyström T, Norhammar A (2016)
Sulphonylurea compared to DPP-4 inhibitors in combination with metformin carries increased risk of severe hypoglycemia, cardiovascular events, and all-cause mortality
Diabetes Res Clin Pract, 117, 39-47
DOI 10.1016/j.diabres.2016.04.055, PubMed 27329021

Hasvold P, Thuresson M, Sundström J, Hammar N, Kjeldsen SE, Johansson G, Holme I, Bodegård J (2016)
Association Between Paradoxical HDL Cholesterol Decrease and Risk of Major Adverse Cardiovascular Events in Patients Initiated on Statin Treatment in a Primary Care Setting
Clin Drug Investig, 36 (3), 225-33
DOI 10.1007/s40261-015-0372-9, PubMed 26718960

Johnston N, Bodegard J, Jerström S, Åkesson J, Brorsson H, Alfredsson J, Albertsson PA, Karlsson JE, Varenhorst C (2016)
Effects of interactive patient smartphone support app on drug adherence and lifestyle changes in myocardial infarction patients: A randomized study
Am Heart J, 178, 85-94
DOI 10.1016/j.ahj.2016.05.005, PubMed 27502855

Kalkan A, Bodegard J, Sundström J, Svennblad B, Östgren CJ, Nilsson PN, Johansson G, Ekman M (2016)
Increased healthcare utilization costs following initiation of insulin treatment in type 2 diabetes: A long-term follow-up in clinical practice
Prim Care Diabetes, 11 (2), 184-192
DOI 10.1016/j.pcd.2016.11.002, PubMed 27894781

Norhammar A, Bodegård J, Nyström T, Thuresson M, Eriksson JW, Nathanson D (2016)
Incidence, prevalence and mortality of type 2 diabetes requiring glucose-lowering treatment, and associated risks of cardiovascular complications: a nationwide study in Sweden, 2006-2013
Diabetologia, 59 (8), 1692-701
DOI 10.1007/s00125-016-3971-y, PubMed 27189067

Nyström T, Bodegard J, Nathanson D, Thuresson M, Norhammar A, Eriksson JW (2016)
Second line initiation of insulin compared with DPP-4 inhibitors after metformin monotherapy is associated with increased risk of all-cause mortality, cardiovascular events, and severe hypoglycemia
Diabetes Res Clin Pract, 123, 199-208
DOI 10.1016/j.diabres.2016.12.004, PubMed 28056431

Publications 2015

Carlborg A, Thuresson M, Ferntoft L, Bodegard J (2015)
Characteristics of bipolar disorder patients treated with immediate- and extended-release quetiapine in a real clinical setting: a longitudinal, cohort study of 1761 patients
Ther Adv Psychopharmacol, 5 (1), 13-21
DOI 10.1177/2045125314560740, PubMed 25653826

Grundvold I, Bodegard J, Nilsson PM, Svennblad B, Johansson G, Östgren CJ, Sundström J (2015)
Body weight and risk of atrial fibrillation in 7,169 patients with newly diagnosed type 2 diabetes; an observational study
Cardiovasc Diabetol, 14, 5
DOI 10.1186/s12933-014-0170-3, PubMed 25589001

Sabale U, Bodegård J, Sundström J, Östgren CJ, Nilsson P, Johansson G, Svennblad B, Henriksson M (2015)
Healthcare utilization and costs following newly diagnosed type-2 diabetes in Sweden: A follow-up of 38,956 patients in a clinical practice setting
Prim Care Diabetes, 9 (5), 330-7
DOI 10.1016/j.pcd.2015.01.001, PubMed 25631469

Publications 2014

Carlborg A, Ferntoft L, Thuresson M, Bodegard J (2014)
Population study of disease burden, management, and treatment of bipolar disorder in Sweden: a retrospective observational registry study
Bipolar Disord, 17 (1), 76-85
DOI 10.1111/bdi.12234, PubMed 25056132

Engeseth K, Hodnesdal C, Grundvold I, Liestøl K, Gjesdal K, Erikssen G, Kjeldsen SE, Erikssen JE, Bodegard J, Skretteberg PT (2014)
Heart rate reserve predicts cardiovascular death among physically unfit but otherwise healthy middle-aged men: a 35-year follow-up study
Eur J Prev Cardiol, 23 (1), 59-66
DOI 10.1177/2047487314553202, PubMed 25281482

Hasvold LP, Bodegård J, Thuresson M, Stålhammar J, Hammar N, Sundström J, Russell D, Kjeldsen SE (2014)
Diabetes and CVD risk during angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker treatment in hypertension: a study of 15,990 patients
J Hum Hypertens, 28 (11), 663-9
DOI 10.1038/jhh.2014.43, PubMed 25211055

Sabale U, Bodegård J, Sundström J, Svennblad B, Östgren CJ, Nilsson P, Johansson G, Henriksson M (2014)
Association of Changes In Body Weight With Health Care Costs Among Patients With Newly-Diagnosed Type-2 Diabetes In Sweden
Value Health, 17 (7), A338
DOI 10.1016/j.jval.2014.08.660, PubMed 27200610

Publications 2013

Bodegard J, Sundström J, Svennblad B, Östgren CJ, Nilsson PM, Johansson G (2013)
Changes in body mass index following newly diagnosed type 2 diabetes and risk of cardiovascular mortality: a cohort study of 8486 primary-care patients
Diabetes Metab, 39 (4), 306-13
DOI 10.1016/j.diabet.2013.05.004, PubMed 23871502

Grundvold I, Skretteberg PT, Engeseth K, Gjesdal K, Kjeldsen SE, Arnesen H, Bodegard J, Liestøl K, Erikssen G, Erikssen J (2013)
Response to Letter by Morris et al regarding article, "Low heart rates predict incident atrial fibrillation in healthy middle-aged men" by Grundvold et al
Circ Arrhythm Electrophysiol, 6 (6), e102
DOI 10.1161/CIRCEP.113.001154, PubMed 24347602

Grundvold I, Skretteberg PT, Liestøl K, Erikssen G, Engeseth K, Gjesdal K, Kjeldsen SE, Arnesen H, Erikssen J, Bodegard J (2013)
Low heart rates predict incident atrial fibrillation in healthy middle-aged men
Circ Arrhythm Electrophysiol, 6 (4), 726-31
DOI 10.1161/CIRCEP.113.000267, PubMed 23873309

Hedberg J, Sundström J, Thuresson M, Aarskog P, Oldgren J, Bodegard J (2013)
Low-dose acetylsalicylic acid and gastrointestinal ulcers or bleeding--a cohort study of the effects of proton pump inhibitor use patterns
J Intern Med, 274 (4), 371-80
DOI 10.1111/joim.12103, PubMed 23800296

Skretteberg PT, Grundvold I, Kjeldsen SE, Engeseth K, Liestøl K, Erikssen G, Erikssen J, Gjesdal K, Bodegard J (2013)
Seven-year increase in exercise systolic blood pressure at moderate workload predicts long-term risk of coronary heart disease and mortality in healthy middle-aged men
Hypertension, 61 (5), 1134-40
DOI 10.1161/HYPERTENSIONAHA.111.00793, PubMed 23529164

Skretteberg PT, Grytten AN, Gjertsen K, Grundvold I, Kjeldsen SE, Erikssen J, Mellbin L, Liestøl K, Fraser DA, Erikssen G, Pedersen TR, Bodegard J (2013)
Triglycerides-diabetes association in healthy middle-aged men: modified by physical fitness? A long term follow-up of 1962 Norwegian men in the Oslo Ischemia Study
Diabetes Res Clin Pract, 101 (2), 201-9
DOI 10.1016/j.diabres.2013.06.001, PubMed 23827210

Sundström J, Sheikhi R, Ostgren CJ, Svennblad B, Bodegård J, Nilsson PM, Johansson G (2013)
Blood pressure levels and risk of cardiovascular events and mortality in type-2 diabetes: cohort study of 34 009 primary care patients
J Hypertens, 31 (8), 1603-10
DOI 10.1097/HJH.0b013e32836123aa, PubMed 23625112

Publications 2012

Grundvold I, Skretteberg PT, Liestøl K, Erikssen G, Kjeldsen SE, Arnesen H, Erikssen J, Bodegard J (2012)
Upper normal blood pressures predict incident atrial fibrillation in healthy middle-aged men: a 35-year follow-up study
Hypertension, 59 (2), 198-204
DOI 10.1161/HYPERTENSIONAHA.111.179713, PubMed 22252392

Grundvold I, Skretteberg PT, Liestøl K, Gjesdal K, Erikssen G, Kjeldsen SE, Arnesen H, Erikssen J, Bodegard J (2012)
Importance of physical fitness on predictive effect of body mass index and weight gain on incident atrial fibrillation in healthy middle-age men
Am J Cardiol, 110 (3), 425-32
DOI 10.1016/j.amjcard.2012.03.043, PubMed 22579085

Hodnesdal C, Prestgaard E, Erikssen G, Gjesdal K, Kjeldsen SE, Liestol K, Skretteberg PT, Erikssen J, Bodegard J (2012)
Rapidly upsloping ST-segment on exercise ECG: a marker of reduced coronary heart disease mortality risk
Eur J Prev Cardiol, 20 (4), 541-8
DOI 10.1177/2047487312444370, PubMed 22492865

Publications 2011

Bodegard J, Skretteberg PT, Gjesdal K, Pyörälä K, Kjeldsen SE, Liestøl K, Erikssen G, Erikssen J (2011)
Low-grade systolic murmurs in healthy middle-aged individuals: innocent or clinically significant? A 35-year follow-up study of 2014 Norwegian men
J Intern Med, 271 (6), 581-8
DOI 10.1111/j.1365-2796.2011.02480.x, PubMed 22061296

Skretteberg PT, Grundvold I, Kjeldsen SE, Erikssen JE, Sandvik L, Liestøl K, Erikssen G, Pedersen TR, Bodegard J (2011)
HDL-cholesterol and prediction of coronary heart disease: modified by physical fitness? A 28-year follow-up of apparently healthy men
Atherosclerosis, 220 (1), 250-6
DOI 10.1016/j.atherosclerosis.2011.10.009, PubMed 22062589

Publications 2010

Henriksson M, Russell D, Bodegard J, Kjeldsen S, Hasvold P, Stålhammar J, Levin LÅ (2010)
Health-care costs of losartan and candesartan in the primary treatment of hypertension
J Hum Hypertens, 25 (2), 130-6
DOI 10.1038/jhh.2010.36, PubMed 20376078

Russell D, Stålhammar J, Bodegard J, Hasvold P, Thuresson M, Kjeldsen SE (2010)
Cardiovascular events in subgroups of patients during primary treatment of hypertension with candesartan or losartan
J Clin Hypertens (Greenwich), 13 (3), 189-97
DOI 10.1111/j.1751-7176.2010.00410.x, PubMed 21366850

Skretteberg PT, Bodegård J, Kjeldsen SE, Erikssen G, Thaulow E, Sandvik L, Erikssen JE (2010)
Interaction between inflammation and blood viscosity predicts cardiovascular mortality
Scand Cardiovasc J, 44 (2), 107-12
DOI 10.1080/14017430903171248, PubMed 19670036

Publications 2009

Kjeldsen SE, Stålhammar J, Hasvold P, Bodegard J, Olsson U, Russell D (2009)
Effects of losartan vs candesartan in reducing cardiovascular events in the primary treatment of hypertension
J Hum Hypertens, 24 (4), 263-73
DOI 10.1038/jhh.2009.77, PubMed 19890371

Publications 2006

Bodegård J (2006)
Cardiovascular long term risk and exercise test findings: 2014 apparently healthy middle aged men followed for 26 years
University of Oslo, Faculty of Medicine, [Oslo], 1 b. (flere pag.)
BIBSYS 060926953, ISBN 82-8072-672-1

Publications 2005

Bodegard J, Erikssen G, Bjørnholt JV, Gjesdal K, Liestøl K, Erikssen J (2005)
Reasons for terminating an exercise test provide independent prognostic information: 2014 apparently healthy men followed for 26 years
Eur Heart J, 26 (14), 1394-401
DOI 10.1093/eurheartj/ehi278, PubMed 15855193

Gulati G, Bodegard J (2005)
[Long term prognosis in relation to the presence of systolic heart murmurs in healthy middle-aged men]
Tidsskr Nor Laegeforen, 125 (9), 1157-8
PubMed 15880150

Publications 2004

Bodegard J, Erikssen G, Bjornholt JV, Thelle D, Erikssen J (2004)
Possible angina detected by the WHO angina questionnaire in apparently healthy men with a normal exercise ECG: coronary heart disease or not? A 26 year follow up study
Heart, 90 (6), 627-32
DOI 10.1136/hrt.2003.012542, PubMed 15145862

Bodegard J, Erikssen G, Bjørnholt JV, Gjesdal K, Thelle D, Erikssen J (2004)
Symptom-limited exercise testing, ST depressions and long-term coronary heart disease mortality in apparently healthy middle-aged men
Eur J Cardiovasc Prev Rehabil, 11 (4), 320-7
DOI 10.1097/01.hjr.0000136460.57921.46, PubMed 15292766

Erikssen G, Bodegard J, Bjørnholt JV, Liestøl K, Thelle DS, Erikssen J (2004)
Exercise testing of healthy men in a new perspective: from diagnosis to prognosis
Eur Heart J, 25 (11), 978-86
DOI 10.1016/j.ehj.2004.04.009, PubMed 15172470

Erikssen G, Bodegard J, Erikssen J (2004)
[Exercise ECG]
Tidsskr Nor Laegeforen, 124 (3), 339-41
PubMed 14963507

Publications 2003

Bjørnholt JV, Erikssen G, Kjeldsen SE, Bodegård J, Thaulow E, Erikssen J (2003)
Fasting blood glucose is independently associated with resting and exercise blood pressures and development of elevated blood pressure
J Hypertens, 21 (7), 1383-9
DOI 10.1097/00004872-200307000-00029, PubMed 12817188

Publications 2002

Bodegard J, Erikssen G, Sandvik L, Kjeldsen SE, Bjørnholt J, Erikssen JE (2002)
Early versus late morning measurement of blood pressure in healthy men. A potential source of measurement bias?
Blood Press, 11 (6), 366-70
DOI 10.1080/080370502321095339, PubMed 12523680